Immuron Ltd ADR (IMRN) - Total Liabilities
Based on the latest financial reports, Immuron Ltd ADR (IMRN) has total liabilities worth $2.06 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Immuron Ltd ADR to assess how effectively this company generates cash.
Immuron Ltd ADR - Total Liabilities Trend (2001–2025)
This chart illustrates how Immuron Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. Check IMRN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Immuron Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Immuron Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gencell Ltd
TA:GNCL
|
Israel | ILA4.38 Million |
|
Rolling Optics Holding AB (publ)
ST:RO
|
Sweden | Skr29.62 Million |
|
Biomerica Inc
NASDAQ:BMRA
|
USA | $1.60 Million |
|
Sewon E&C
KO:091090
|
Korea | ₩110.01 Billion |
|
AHB Holdings Bhd
KLSE:7315
|
Malaysia | RM2.05 Million |
|
Diriteks Dirilis Tekstil Sanayi ve Ticaret AS
IS:DIRIT
|
Turkey | TL13.74 Million |
|
Ansal Properties & Infrastructure Limited
NSE:ANSALAPI
|
India | Rs7.61 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Immuron Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Immuron Ltd ADR market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immuron Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immuron Ltd ADR (2001–2025)
The table below shows the annual total liabilities of Immuron Ltd ADR from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $2.06 Million | -27.45% |
| 2024-06-30 | $2.84 Million | +19.79% |
| 2023-06-30 | $2.37 Million | +41.28% |
| 2022-06-30 | $1.68 Million | +44.94% |
| 2021-06-30 | $1.16 Million | +107.44% |
| 2020-06-30 | $558.25K | -53.88% |
| 2019-06-30 | $1.21 Million | +50.69% |
| 2018-06-30 | $803.34K | -53.06% |
| 2017-06-30 | $1.71 Million | -55.97% |
| 2016-06-30 | $3.89 Million | +221.82% |
| 2015-06-30 | $1.21 Million | +42.89% |
| 2014-06-30 | $845.30K | -64.51% |
| 2013-06-30 | $2.38 Million | +49.95% |
| 2012-06-30 | $1.59 Million | +71.18% |
| 2011-06-30 | $927.84K | +113.25% |
| 2010-06-30 | $435.10K | -35.82% |
| 2009-06-30 | $677.90K | -14.16% |
| 2008-06-30 | $789.69K | -39.80% |
| 2007-06-30 | $1.31 Million | -5.39% |
| 2006-06-30 | $1.39 Million | +27.02% |
| 2005-06-30 | $1.09 Million | +31.25% |
| 2004-06-30 | $831.69K | +227.64% |
| 2002-06-30 | $253.84K | -28.75% |
| 2001-06-30 | $356.28K | -- |
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more